ATE336239T1 - Neue fettsäureanaloge zur behandlung des bluthochdrucks - Google Patents

Neue fettsäureanaloge zur behandlung des bluthochdrucks

Info

Publication number
ATE336239T1
ATE336239T1 AT02024616T AT02024616T ATE336239T1 AT E336239 T1 ATE336239 T1 AT E336239T1 AT 02024616 T AT02024616 T AT 02024616T AT 02024616 T AT02024616 T AT 02024616T AT E336239 T1 ATE336239 T1 AT E336239T1
Authority
AT
Austria
Prior art keywords
sub
hypertension
treatment
fatty acid
acid analogues
Prior art date
Application number
AT02024616T
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Application granted granted Critical
Publication of ATE336239T1 publication Critical patent/ATE336239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Saccharide Compounds (AREA)
  • Edible Oils And Fats (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02024616T 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks ATE336239T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Publications (1)

Publication Number Publication Date
ATE336239T1 true ATE336239T1 (de) 2006-09-15

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
AT02024616T ATE336239T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications After (4)

Application Number Title Priority Date Filing Date
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Country Status (17)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1075258B1 (de)
JP (3) JP5057003B2 (de)
KR (3) KR100701502B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE336239T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910296A (de)
CA (3) CA2331408C (de)
DE (5) DE69932645D1 (de)
DK (3) DK1075259T3 (de)
ES (3) ES2207253T3 (de)
NO (3) NO20005463L (de)
NZ (3) NZ508047A (de)
PT (2) PT1075259E (de)
RU (3) RU2221558C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
JP4433496B2 (ja) * 2002-05-28 2010-03-17 味の素株式会社 Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用
RU2331649C2 (ru) * 2002-06-20 2008-08-20 Ай-Си Ви-И-Си Лимитед Серосодержащие фосфолипидные производные, содержащая их фармацевтическая композиция, их применение для лечения заболеваний и способ их получения
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
EP1545532A2 (de) 2002-09-06 2005-06-29 Janssen Pharmaceutica N.V. Heterozyklische verbindungen
BR0314799A (pt) * 2002-09-27 2005-07-26 Market Biosciences Corp Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
KR20050071565A (ko) * 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
RU2356247C2 (ru) * 2003-03-18 2009-05-27 Новартис Аг Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
JP2008501110A (ja) * 2004-05-28 2008-01-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 覚醒ラットにおける新しい静脈内薬物投与および血液サンプリングモデル
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
RU2394598C2 (ru) * 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
EP1784223A2 (de) * 2004-07-19 2007-05-16 Thia Medica AS Zusammensetzung enthaltend pflanzen- oder fischöl und nicht-oxidierbaren fettsäuren
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
EP1888728A4 (de) * 2005-05-04 2010-07-14 Pronova Biopharma Norge As Fettsäureanaloge, d. h. dha-derivate zur verwendung als medikament
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
SI2724722T1 (sl) 2006-10-20 2017-07-31 Neurendo Pharma, Llc Postopek za obnovitev učinka inkretina
MX2009004337A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Compuestos lipidos omega-3.
JP5552313B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
EP2214481B1 (de) 2007-10-15 2019-05-01 United Animal Health, Inc. Verfahren zur erhöhung der leistung von nachkommen
EP2217558A1 (de) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS Neue dha-derivate und ihre verwendung als medikamente
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2722114A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
NZ596386A (en) 2009-05-08 2014-01-31 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
UA111475C2 (uk) 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2014132134A1 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
AU2014229506B2 (en) 2013-03-11 2017-04-13 Nobesita As Natural lipids containing non-oxidizable fatty acids
EP2983658B1 (de) 2013-03-11 2024-05-01 Sciadonics, Inc. Lipidzusammensetzungen mit bioaktiven fettsäuren
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2019083816A1 (en) * 2017-10-23 2019-05-02 Epitracker, Inc. FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME
EP3720431B1 (de) 2017-12-06 2024-10-30 Basf As Fettsäurederivate zur behandlung von nicht-alkoholischer steatohepatitis
CA3099482A1 (en) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
EP3934639A4 (de) 2019-03-04 2023-01-11 Epitracker, Inc. Fettsäureanaloge und deren verwendung zur behandlung von kognitiven beeinträchtigungen, verhaltenszuständen und chronischen schmerzen
JP2024539823A (ja) 2021-11-03 2024-10-31 エピトラッカー インコーポレイテッド 老化の質および寿命に関係する状態の治療のためのペンタデカノイルカルニチン
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 N.V. Nutricia, Zoetermeer Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
DK1075260T3 (da) 2006-02-06
US20020198259A1 (en) 2002-12-26
KR20010043314A (ko) 2001-05-25
DE69909775T2 (de) 2004-06-03
ATE334666T1 (de) 2006-08-15
EP1285652B1 (de) 2006-08-16
RU2219920C2 (ru) 2003-12-27
NZ508045A (en) 2003-08-29
DE69909775D1 (de) 2003-08-28
EP1075260B1 (de) 2005-10-19
HK1034912A1 (en) 2001-11-09
WO1999058120A1 (en) 1999-11-18
EP1075259A1 (de) 2001-02-14
CA2331393A1 (en) 1999-11-18
NO20005462D0 (no) 2000-10-30
CA2331408A1 (en) 1999-11-18
JP2002514596A (ja) 2002-05-21
AU4936799A (en) 1999-11-29
KR20010043316A (ko) 2001-05-25
WO1999058121A1 (en) 1999-11-18
EP1075260A2 (de) 2001-02-14
CN1223343C (zh) 2005-10-19
DE69932645D1 (de) 2006-09-14
JP4465672B2 (ja) 2010-05-19
CN1300212A (zh) 2001-06-20
US7026356B2 (en) 2006-04-11
AU761355B2 (en) 2003-06-05
RU2223095C2 (ru) 2004-02-10
WO1999058123A3 (en) 2000-03-09
DK1075259T3 (da) 2003-11-03
EP1075258A1 (de) 2001-02-14
ATE247464T1 (de) 2003-09-15
DE69932864D1 (de) 2006-09-28
KR20010043315A (ko) 2001-05-25
PT1075258E (pt) 2004-01-30
AU762792B2 (en) 2003-07-03
CN1300211A (zh) 2001-06-20
ATE245416T1 (de) 2003-08-15
ATE306916T1 (de) 2005-11-15
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
NO20005463L (no) 2001-01-08
CN1302204A (zh) 2001-07-04
JP2002514594A (ja) 2002-05-21
ES2251218T3 (es) 2006-04-16
JP5057003B2 (ja) 2012-10-24
HK1034911A1 (en) 2001-11-09
DK1075258T3 (da) 2003-12-01
DE69927805D1 (de) 2006-03-02
CN1245157C (zh) 2006-03-15
AU7240398A (en) 1999-11-29
AU762790B2 (en) 2003-07-03
NO20005461L (no) 2001-01-08
NO333143B1 (no) 2013-03-18
EP1284139B1 (de) 2006-08-02
KR100701502B1 (ko) 2007-04-02
EP1285652A1 (de) 2003-02-26
RU2221558C2 (ru) 2004-01-20
US6365628B1 (en) 2002-04-02
CA2331393C (en) 2009-08-11
EP1075258B1 (de) 2003-08-20
NZ508047A (en) 2003-05-30
US6417232B1 (en) 2002-07-09
ES2204142T3 (es) 2004-04-16
AU5451799A (en) 1999-11-29
PT1075259E (pt) 2003-12-31
JP2002514595A (ja) 2002-05-21
HK1034909A1 (en) 2001-11-09
CA2331395C (en) 2008-10-14
BR9910296A (pt) 2002-01-15
EP1284139A1 (de) 2003-02-19
DE69910559T2 (de) 2004-06-17
WO1999058123A2 (en) 1999-11-18
NO20005463D0 (no) 2000-10-30
KR100701503B1 (ko) 2007-04-02
NO20005462L (no) 2001-01-08
DE69927805T2 (de) 2006-07-06
EP1075259B1 (de) 2003-07-23
CN1244323C (zh) 2006-03-08
KR100822077B1 (ko) 2008-04-14
NZ508046A (en) 2003-08-29
CA2331395A1 (en) 1999-11-18
DE69910559D1 (de) 2003-09-25
AU4936699A (en) 1999-11-29
WO1999058122A1 (en) 1999-11-18
CA2331408C (en) 2008-10-21
US6441036B1 (en) 2002-08-27
NO20005461D0 (no) 2000-10-30

Similar Documents

Publication Publication Date Title
DE69932864D1 (de) Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
DE60133716D1 (de) Verwendungen eines getränks enthaltend ein polyphosphat zur behandlung von zahnerosionen
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
BR0212899A (pt) Compostos orgânicos
ATE418974T1 (de) Fettsäure-analogen zur behandlung proliferierender hautstörungen
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
ID27440A (id) Proses untuk menyiapkan penengah-penengah
DE60204014D1 (de) Chlormethylierung von thiophene
MXPA03010821A (es) Composiciones de aroma y fragancias.
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh
BR0316971A (pt) Fenilalquinas
YU70799A (sh) Derivati tiazofurina
ATE327235T1 (de) 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties